首页> 美国卫生研究院文献>other >Phase II study of dasatinib in patients with previously treated malignant mesothelioma (Cancer and Leukemia Group B 30601): a brief report

【2h】

Phase II study of dasatinib in patients with previously treated malignant mesothelioma (Cancer and Leukemia Group B 30601): a brief report

机译：达沙替尼对患者达司替尼治疗的恶性间皮瘤（癌症和白血病B组30601）的II期研究：简要报告

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

IntroductionWe conducted a phase II trial of dasatinib in malignant mesothelioma (MM) patients to evaluate its toxicity and efficacy as a second-line treatment.

机译：简介我们在恶性间皮瘤（MM）患者中进行了达斯替尼试验，以评估其作为二线治疗的毒性和功效。

著录项

期刊名称 other
作者
Arkadiusz Z. Dudek; Herbert Pang; Robert A. Kratzke; Gregory A. Otterson; Lydia Hodgson; Everett E. Vokes; Hedy L. Kindler;
展开▼
作者单位

展开▼
年(卷),期 -1(7),4
年度 -1
页码 755–759
总页数 9
原文格式 PDF
正文语种
中图分类
关键词
dasatinib mesothelioma SRC kinase;

机译：达沙替尼;间皮瘤;SRC激酶;

相似文献

外文文献
中文文献
专利

1. Phase II study of dasatinib in patients with previously treated malignant mesothelioma (Cancer and leukemia group B 30601): A brief report [J] . DudekA.Z., PangH., KratzkeR.A., Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2012,第4期

机译：达沙替尼在先前治疗过的恶性间皮瘤患者中的II期研究（癌症和白血病B 30601组）：简要报告
2. Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant ple [J] . Bottomley A, Coens C, Efficace F, Journal of Clinical Oncology . 2007,第36期

机译：症状和患者报告的健康状况：它们是否可预测恶性胸膜间皮瘤的存活率？ EORTC-NCIC 08983的预后因素分析：恶性肿瘤患者顺铂联合有或无雷替曲塞的随机III期研究
3. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Insti [J] . van Meerbeeck JP, Gaafar R, Manegold C, Journal of Clinical Oncology . 2005,第28期

机译：恶性胸膜间皮瘤患者有或没有氨甲蝶呤的顺铂三期随机研究：欧洲肺癌研究和治疗组织和国家癌症研究所的组间研究
4. Cisplatin-Loaded Biodegradable Nanofiber Meshes for Treating Malignant Pleural Mesothelioma [C] . Jonah A Kaplan, Reimi Yonekura, Yolonda L. Colson, Society for biomaterials annual meeting and exposition . 2013

机译：顺铂生物降解纳米纤维网片治疗恶性胸膜间皮瘤
5. Association of patient-reported outcomes with progression-free survival in malignant pleural mesothelioma. [D] . Hackshaw, Michelle Denise. 2010

机译：患者报告的结局与恶性胸膜间皮瘤无进展生存的相关性。
6. Amrubicin in previously treated patients with malignant pleural mesothelioma: A phase II study [O] . Takaya Ikeda, Shinnosuke Takemoto, Hiroaki Senju, 2020

机译：先前治疗的恶性胸膜间皮瘤患者中的氨柔比星：II期研究
7. Phase II study of dasatinib in patients with previously treated malignant mesothelioma (Cancer and leukemia group B 30601): A brief report [O] . Pang, H, Kindler, HL, Dudek, AZ, 2012

机译：达沙替尼治疗先前治疗过的恶性间皮瘤患者的第二阶段研究（癌症和白血病B组30601）：简要报告

Phase II study of dasatinib in patients with previously treated malignant mesothelioma (Cancer and Leukemia Group B 30601): a brief report

摘要

著录项

相似文献

相关主题

期刊订阅